Projecten per jaar
Samenvatting
mAbs have been instrumental for targeted cancer therapies. However, their relatively large size and physicochemical properties result in a heterogenous distribution in the tumor microenvironment, usually restricted to the first cell layers surrounding blood vessels, and a limited ability to penetrate the brain. Nanobodies are tenfold smaller, resulting in a deeper tumor penetration and the ability to reach cells in poorly perfused tumor areas. Nanobodies are rapidly cleared from the circulation, which generates a fast target-to-background contrast that is ideally suited for molecular imaging purposes but may be less optimal for therapy. To circumvent this problem, nanobodies have been formatted to noncovalently bind albumin, increasing their serum half-life without majorly increasing their size. Finally, nanobodies have shown superior qualities to infiltrate brain tumors as compared to mAbs. In this review, we discuss why these features make nanobodies prime candidates for targeted therapy of cancer.
Originele taal-2 | English |
---|---|
Artikelnummer | e2250024 |
Pagina's (van-tot) | 1-8 |
Aantal pagina's | 8 |
Tijdschrift | European Journal of Immunology |
Volume | 53 |
Nummer van het tijdschrift | 9 |
DOI's | |
Status | Published - sep 2023 |
Bibliografische nota
Funding Information:NAJ, MZ, RMB, and TWMDG are supported by FWO‐Vlaanderen. CV is supported by the EU Innovative Medicines Initiative project Immune‐Image.
Publisher Copyright:
© 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.
Vingerafdruk
Duik in de onderzoeksthema's van 'A few good reasons to use nanobodies for cancer treatment: A few good reasons to use nanobodies for cancer treatment'. Samen vormen ze een unieke vingerafdruk.Projecten
- 1 Actief
-
SRP83: SRP-Onderzoekszwaartepunt: Immunoregulatoire cellen als doelwit voor moleculaire beeldvorming en therapie in inflammatoire ziekten en kanker
Van Ginderachter, J., Lahoutte, T., Lahoutte, T., Van Ginderachter, J., Devoogdt, N., Raes, G., Stijlemans, B., Vincke, C. & De Groof, T.
1/11/22 → 31/10/27
Project: Fundamenteel